MXPA04004105A - Metodo de tratamiento de tinnitus. - Google Patents

Metodo de tratamiento de tinnitus.

Info

Publication number
MXPA04004105A
MXPA04004105A MXPA04004105A MXPA04004105A MXPA04004105A MX PA04004105 A MXPA04004105 A MX PA04004105A MX PA04004105 A MXPA04004105 A MX PA04004105A MX PA04004105 A MXPA04004105 A MX PA04004105A MX PA04004105 A MXPA04004105 A MX PA04004105A
Authority
MX
Mexico
Prior art keywords
acid
aminomethyl
compound
methyl
mmol
Prior art date
Application number
MXPA04004105A
Other languages
English (en)
Spanish (es)
Inventor
James Dooley David
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04004105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA04004105A publication Critical patent/MXPA04004105A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA04004105A 2002-01-31 2003-01-20 Metodo de tratamiento de tinnitus. MXPA04004105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35363202P 2002-01-31 2002-01-31
PCT/IB2003/000232 WO2003063845A1 (en) 2002-01-31 2003-01-20 Alpha 2 delta ligands to treat tinnitus

Publications (1)

Publication Number Publication Date
MXPA04004105A true MXPA04004105A (es) 2004-11-29

Family

ID=27663234

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004105A MXPA04004105A (es) 2002-01-31 2003-01-20 Metodo de tratamiento de tinnitus.

Country Status (16)

Country Link
US (2) US7026505B2 (https=)
EP (1) EP1469841A1 (https=)
JP (1) JP2005521664A (https=)
KR (1) KR20040081478A (https=)
CN (1) CN1625393A (https=)
AU (1) AU2003201716B2 (https=)
BR (1) BR0307411A (https=)
CA (1) CA2474000A1 (https=)
CL (1) CL2008000613A1 (https=)
IL (1) IL162028A0 (https=)
MX (1) MXPA04004105A (https=)
NZ (1) NZ532624A (https=)
PL (1) PL371944A1 (https=)
TW (1) TW200306177A (https=)
WO (1) WO2003063845A1 (https=)
ZA (1) ZA200403069B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BRPI0408110A (pt) 2003-03-07 2006-03-01 Warner Lambert Co derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP1622613A4 (en) * 2003-05-14 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
CN101506140B (zh) * 2006-08-24 2014-06-18 百时美施贵宝公司 环状11β-羟类固醇脱氢酶Ⅰ型抑制剂
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EA200970483A1 (ru) * 2006-11-14 2009-12-30 Ксенопорт, Инк. Применение пролекарств габапентина и прегабалина для лечения шума в ушах
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101260063B (zh) * 2008-03-21 2013-06-19 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1998017627A1 (en) * 1996-10-23 1998-04-30 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
US6518289B1 (en) * 1997-12-16 2003-02-11 Pfizer, Inc. 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
NZ503980A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
DK1045839T3 (da) * 1997-12-16 2004-07-05 Warner Lambert Co Hidtil ukendte aminer som farmaceutiske midler
EP1082306A1 (en) * 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
RS50352B (sr) * 1999-06-10 2009-11-10 Warner-Lambert Company Llc., Monosupstituisane 3-propil gama-aminobuterne kiseline
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage

Also Published As

Publication number Publication date
NZ532624A (en) 2007-05-31
US20060100281A1 (en) 2006-05-11
AU2003201716B2 (en) 2008-04-17
IL162028A0 (en) 2005-11-20
CL2008000613A1 (es) 2008-11-07
TW200306177A (en) 2003-11-16
WO2003063845A1 (en) 2003-08-07
US7138542B2 (en) 2006-11-21
US20030176504A1 (en) 2003-09-18
KR20040081478A (ko) 2004-09-21
CN1625393A (zh) 2005-06-08
EP1469841A1 (en) 2004-10-27
JP2005521664A (ja) 2005-07-21
CA2474000A1 (en) 2003-08-07
PL371944A1 (en) 2005-07-11
ZA200403069B (en) 2005-04-22
US7026505B2 (en) 2006-04-11
BR0307411A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
US9018414B2 (en) Substituted 3-phenylpropionic acids and the use thereof
US10023528B2 (en) Branched 3-phenylpropionic acid derivatives and their use
US9018258B2 (en) Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof
KR100694735B1 (ko) 일치환 및 이치환된 3-프로필 감마-아미노부티르산
MXPA04004105A (es) Metodo de tratamiento de tinnitus.
JP3874403B2 (ja) 軟骨障害を処置する方法
CA2509605C (en) Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2003201716A1 (en) Alpha 2 delta ligands to treat tinnitus
CZ20012758A3 (cs) Větvené aminokyselinově dependentní aminotransferasové inhibitory a jejich použití při léčení diabetické retinopatie
KR20040039394A (ko) 선택적 inos 억제제를 사용한 신경보호적 치료 방법
JP2007506726A (ja) α2δ−タンパク質に対する親和性を有するアミノ酸の使用方法
AU2003303040B2 (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders

Legal Events

Date Code Title Description
FG Grant or registration